Your browser doesn't support javascript.
loading
Therapeutic anti-amyloid ß antibodies cause neuronal disturbances.
Adhikari, Utpal Kumar; Khan, Rizwan; Mikhael, Meena; Balez, Rachelle; David, Monique Antoinette; Mahns, David; Hardy, John; Tayebi, Mourad.
  • Adhikari UK; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
  • Khan R; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
  • Mikhael M; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
  • Balez R; Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia.
  • David MA; School of Chemistry and Molecular Bioscience and Molecular Horizons, University of Wollongong, Wollongong, New South Wales, Australia.
  • Mahns D; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
  • Hardy J; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
  • Tayebi M; Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Alzheimers Dement ; 19(6): 2479-2496, 2023 06.
Article en En | MEDLINE | ID: mdl-36515320
ABSTRACT

INTRODUCTION:

Recent published clinical trial safety data showed that 41% of Alzheimer patients experienced amyloid-related imaging abnormalities (ARIA), marks of microhemorrhages and edema in the brain, following administration of Biogen's Aduhelm/aducanumab (amino acids 3-7 of the Aß peptide). Similarly, Janssen/Pfizer's Bapineuzumab (amino acids 1-5 of the Aß peptide) and Roche's Gantenerumab (amino acids 2-11/18-27 of the Aß peptide) also displayed ARIA in clinical trials, including microhemorrhage and focal areas of inflammation or vasogenic edema, respectively. The molecular mechanisms underlying ARIA caused by therapeutic anti-Aß antibodies remain largely unknown, however, recent reports demonstrated that therapeutic anti-prion antibodies activate neuronal allergenic proteomes following cross-linking cellular prion protein.

METHODS:

Here, we report that treatment of human induced pluripotent stem cells- derived neurons (HSCN) from a non-demented donor, co-cultured with human primary microglia with anti-Aß1-6, or anti-Aß17-23 antibodies activate a significant number of allergenic-related proteins as assessed by mass spectrometry.

RESULTS:

Interestingly, a large proportion of the identified proteins included cytokines such as interleukin (IL)-4, IL-12, and IL-13 suggesting a type-1 hypersensitivity response. Following flow cytometry analysis, several proinflammatory cytokines were significantly elevated following anti-Aß1-6, or anti-Aß17-23 antibody treatment.

DISCUSSION:

These results justify further and more robust investigation of the molecular mechanisms of ARIA during immunotherapy study trials of AD. HIGHLIGHTS Allergenic-related proteins are often linked with Alzheimer's disease (AD). We investigated the effects of amyloid beta (Aß) immunotherapy on stem cell derived neurons and primary neuronal cells co-cultured with microglia. Anti-Aß antibody treatment of neurons or neurons co-cultured with microglia led to activation of a substantial number of allergenic-related genes. These allergenic-related genes are associated with endothelial dysfunction possibly responsible for ARIA.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Enfermedad de Alzheimer Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Enfermedad de Alzheimer Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article